Cargando…
AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa
Base editing technology is an ideal solution for treating pathogenic single-nucleotide variations (SNVs). No gene editing therapy has yet been approved for eye diseases, such as retinitis pigmentosa (RP). Here, we show, in the rd10 mouse model, which carries an SNV identified as an RP-causing mutati...
Autores principales: | Wu, Yidong, Wan, Xiaoling, Zhao, Dongdong, Chen, Xuxu, Wang, Yujie, Tang, Xinxin, Li, Ju, Li, Siwei, Sun, Xiaodong, Bi, Changhao, Zhang, Xueli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427680/ https://www.ncbi.nlm.nih.gov/pubmed/37582961 http://dx.doi.org/10.1038/s41467-023-40655-6 |
Ejemplares similares
-
Imperfect guide-RNA (igRNA) enables CRISPR single-base editing with ABE and CBE
por: Zhao, Dongdong, et al.
Publicado: (2022) -
Allele-specific editing ameliorates dominant retinitis pigmentosa in a transgenic mouse model
por: Patrizi, Clarissa, et al.
Publicado: (2021) -
AAV-Txnip prolongs cone survival and vision in mouse models of retinitis pigmentosa
por: Xue, Yunlu, et al.
Publicado: (2021) -
Automated high-throughput genome editing platform with an AI learning in situ prediction model
por: Li, Siwei, et al.
Publicado: (2022) -
Genome editing of Ralstonia eutropha using an electroporation-based CRISPR-Cas9 technique
por: Xiong, Bin, et al.
Publicado: (2018)